125 related articles for article (PubMed ID: 37469041)
1. Does Prescription Length of Buprenorphine Influence Treatment Outcomes in Opioid Use Disorder? A Retrospective Cohort Study from North India.
Ghosh A; Mahintamani T; Kathiravan S; Swer SB; Basu D; Mattoo SK; B N S; Singh A
Subst Use Misuse; 2023; 58(12):1620-1624. PubMed ID: 37469041
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
[TBL] [Abstract][Full Text] [Related]
3. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
Worley MJ; Heinzerling KG; Shoptaw S; Ling W
Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
[TBL] [Abstract][Full Text] [Related]
4. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
5. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
Wachman EM; Saia K; Miller M; Valle E; Shrestha H; Carter G; Werler M; Jones H
Clin Ther; 2019 Sep; 41(9):1681-1689. PubMed ID: 31358302
[TBL] [Abstract][Full Text] [Related]
6. Mobile, Community-Based Buprenorphine Treatment for Veterans Experiencing Homelessness With Opioid Use Disorder: A Pilot, Feasibility Study.
Iheanacho T; Payne K; Tsai J
Am J Addict; 2020 Nov; 29(6):485-491. PubMed ID: 32367557
[TBL] [Abstract][Full Text] [Related]
7. Lower buprenorphine elimination rate constant is associated with lower opioid use.
Elarabi HF; Lee AJ; Adem A; Elrasheed A; Marsden J; Al Ghaferi H
Psychopharmacology (Berl); 2022 Oct; 239(10):3213-3221. PubMed ID: 35953563
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy.
Perry BN; Vais S; Boateng JO; Jain M; Wachman EM; Saia KA
J Addict Med; 2022 Nov-Dec 01; 16(6):e399-e404. PubMed ID: 35916423
[TBL] [Abstract][Full Text] [Related]
10. Depression and Buprenorphine Treatment in Patients with Non-cancer Pain and Prescription Opioid Dependence without Comorbid Substance Use Disorders.
Scherrer JF; Salas J; Grucza R; Sullivan MD; Lustman PJ; Copeland LA; Ballantyne JC
J Affect Disord; 2021 Jan; 278():563-569. PubMed ID: 33022442
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
12. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
[TBL] [Abstract][Full Text] [Related]
14. Perioperative Management of Buprenorphine: Solving the Conundrum.
Quaye AN; Zhang Y
Pain Med; 2019 Jul; 20(7):1395-1408. PubMed ID: 30500943
[TBL] [Abstract][Full Text] [Related]
15. Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts.
Hasan MM; Noor-E-Alam M; Mohite P; Islam MS; Modestino AS; Peckham AM; Young LD; Young GJ
J Subst Abuse Treat; 2021 Dec; 131():108416. PubMed ID: 34098294
[TBL] [Abstract][Full Text] [Related]
16. A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders.
Dayal P; Balhara YPS
J Subst Abuse Treat; 2017 Sep; 80():1-5. PubMed ID: 28755768
[TBL] [Abstract][Full Text] [Related]
17. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.
Jakubowski A; Lu T; DiRenno F; Jadow B; Giovanniello A; Nahvi S; Cunningham C; Fox A
J Subst Abuse Treat; 2020 Dec; 119():108140. PubMed ID: 33138925
[TBL] [Abstract][Full Text] [Related]
18. Does the Addition of Naloxone in Buprenorphine/Naloxone Affect Retention in Treatment in Opioid Replacement Therapy?: A Systematic Review and Meta-Analysis.
Dalton K; Butt N
J Addict Nurs; 2019; 30(4):254-260. PubMed ID: 31800516
[TBL] [Abstract][Full Text] [Related]
19. Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone.
Mannelli P; Douaihy AB; Zavod A; Legedza A; Akerman SC; Sullivan MA
Am J Drug Alcohol Abuse; 2021 Nov; 47(6):753-759. PubMed ID: 34752714
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine alone or with naloxone: Which is safer?
Kelty E; Cumming C; Troeung L; Hulse G
J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
